Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update

2020 ◽  
Vol 30 (4) ◽  
pp. 436-440 ◽  
Author(s):  
Christina Fotopoulou ◽  
Nicole Concin ◽  
François Planchamp ◽  
Philippe Morice ◽  
Ignace Vergote ◽  
...  
2016 ◽  
Vol 26 (7) ◽  
pp. 1354-1363 ◽  
Author(s):  
Denis Querleu ◽  
François Planchamp ◽  
Luis Chiva ◽  
Christina Fotopoulou ◽  
Desmond Barton ◽  
...  

Author(s):  
Marie-Mélanie Gac ◽  
Cécile Loaec ◽  
Johanna Silve ◽  
Edouard Vaucel ◽  
Paule Augereau ◽  
...  

2021 ◽  
pp. ijgc-2021-002951 ◽  
Author(s):  
Christina Fotopoulou ◽  
François Planchamp ◽  
Tugce Aytulu ◽  
Luis Chiva ◽  
Alessandro Cina ◽  
...  

The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, and updated in 2020, quality indicators for advanced ovarian cancer surgery to audit and improve clinical practice in Europe and beyond. As a sequela of the continuous effort to improve oncologic care in patients with ovarian cancer, ESGO issued in 2018 a consensus guidance jointly with the European Society of Medical Oncology addressing in a multidisciplinary fashion 20 selected key questions in the management of ovarian cancer, ranging from molecular pathology to palliation in primary and relapse disease. In order to complement the above achievements and consolidate the promoted systemic advances and surgical expertise with adequate peri-operative management, ESGO developed, as the next step, clinically relevant and evidence-based guidelines focusing on key aspects of peri-operative care and management of complications as part of its mission to improve the quality of care for women with advanced ovarian cancer and reduce iatrogenic morbidity. To do so, ESGO nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of ovarian cancer (18 experts across Europe). To ensure that the guidelines are evidence based, the literature published since 2015, identified from a systematic search, was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 117 independent international practitioners in cancer care delivery and patient representatives.


2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Antoni Llueca ◽  
◽  
Anna Serra ◽  
Maria Teresa Climent ◽  
Blanca Segarra ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


2013 ◽  
Vol 24 (11) ◽  
pp. 2732-2739 ◽  
Author(s):  
D. Querleu ◽  
I. Ray-Coquard ◽  
J.M. Classe ◽  
J.S. Aucouturier ◽  
F. Bonnet ◽  
...  

2005 ◽  
Vol 97 (2) ◽  
pp. 446-456 ◽  
Author(s):  
Anna R. Gagliardi ◽  
Michael Fung Kee Fung ◽  
Bernard Langer ◽  
Hartley Stern ◽  
Adalsteinn D. Brown

Sign in / Sign up

Export Citation Format

Share Document